Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma : experience in six cases
It has been reported that cisplatin-based chemotherapy shows beneficial effects in certain patients with advanced thymic carcinoma. However, the usefulness of salvage therapy has not been reported. We focused on a new anthracycline agent, amrubicin, combined with platinum compounds as salvage chemotherapy in patients with thymic carcinoma. Six cases of unresectable and locally advanced thymic carcinoma relapsed from prior cisplatin-containing chemotherapy were treated with amrubicin (30-40 mg/m(2) day 1-3) plus platinum compounds (cisplatin 60 mg/m(2) day 1 or nedaplatin 70 mg/m(2) day 1) chemotherapy as salvage chemotherapy. Two patients showed a partial response. However, Grade 3/4 neutropenia and thrombocytopenia occurred in all and two of the patients, respectively. We conclude that thymic carcinoma is sensitive to platinum-based chemotherapy and that amrubicin appears to have significant activity against thymic carcinoma. The major toxicity is hematological toxicities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Medical oncology (Northwood, London, England) - 27(2010), 2 vom: 30. Juni, Seite 392-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koizumi, Tomonobu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
93N13LB4Z2 |
|---|
| Anmerkungen: |
Date Completed 12.01.2011 Date Revised 20.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12032-009-9223-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM188274545 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM188274545 | ||
| 003 | DE-627 | ||
| 005 | 20231223181633.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12032-009-9223-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0628.xml |
| 035 | |a (DE-627)NLM188274545 | ||
| 035 | |a (NLM)19415537 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koizumi, Tomonobu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma |b experience in six cases |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2011 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a It has been reported that cisplatin-based chemotherapy shows beneficial effects in certain patients with advanced thymic carcinoma. However, the usefulness of salvage therapy has not been reported. We focused on a new anthracycline agent, amrubicin, combined with platinum compounds as salvage chemotherapy in patients with thymic carcinoma. Six cases of unresectable and locally advanced thymic carcinoma relapsed from prior cisplatin-containing chemotherapy were treated with amrubicin (30-40 mg/m(2) day 1-3) plus platinum compounds (cisplatin 60 mg/m(2) day 1 or nedaplatin 70 mg/m(2) day 1) chemotherapy as salvage chemotherapy. Two patients showed a partial response. However, Grade 3/4 neutropenia and thrombocytopenia occurred in all and two of the patients, respectively. We conclude that thymic carcinoma is sensitive to platinum-based chemotherapy and that amrubicin appears to have significant activity against thymic carcinoma. The major toxicity is hematological toxicities | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anthracyclines |2 NLM | |
| 650 | 7 | |a Antibiotics, Antineoplastic |2 NLM | |
| 650 | 7 | |a Platinum Compounds |2 NLM | |
| 650 | 7 | |a amrubicin |2 NLM | |
| 650 | 7 | |a 93N13LB4Z2 |2 NLM | |
| 700 | 1 | |a Agatsuma, Toshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Ichiyama, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Yokoyama, Toshiki |e verfasserin |4 aut | |
| 700 | 1 | |a Ushiki, Atsuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Komatsu, Yoshimichi |e verfasserin |4 aut | |
| 700 | 1 | |a Tanabe, Tsuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshikawa, Sumiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuo, Masanori |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kubo, Keishi |e verfasserin |4 aut | |
| 700 | 1 | |a Hachiya, Tsutomu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical oncology (Northwood, London, England) |d 1997 |g 27(2010), 2 vom: 30. Juni, Seite 392-6 |w (DE-627)NLM075077132 |x 1559-131X |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2010 |g number:2 |g day:30 |g month:06 |g pages:392-6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12032-009-9223-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2010 |e 2 |b 30 |c 06 |h 392-6 | ||